The clinical-stage biotech market is as vast as it is complicated. Companies operating in this space are wide-ranging in the illnesses they look to treat. But when they get it right, these stocks can move in a big way. Today, Longeveron (NASDAQ:LGVN) is the biotech stock getting significant attention, as LGVN stock surged more than 120% in today’s session.In fact, as I’m writing this, LGVN stock has already more than doubled on the day. Indeed, as is the case with most such moves in the biotech sector, inve ...